An interventional study of Everycell™ and Placebo in Family Member, sponsored by University of Miami. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-23.
Sponsored by University of Miami · Not applicable, Interventional, and Basic science
The investigators are conducting this research because they want to determine if a dietary supplement, called Everycell™, has an effect on the functioning of the study participants' cells. The results of this research will be used to help develop additional strategies for trying to fight the effects of aging. The primary purpose of this study is to determine the effectiveness of Everycell™ compared to placebo (a pill that does nothing) on DNA damage, inflammation, stress, and related factors. Taking Everycell™ is not a medical prescription, treatment, or cure for any known disease or condition.
Helping patients' nutritional status is important to prevent the continued worsening of chronic diseases and also to counteract the effects of aging. Americans also have difficulties with compliance to prescription medications due to their toxicity and side effects. This study aims to learn more about how a dietary supplement may improve nutritional status and enable the body to normalize cellular functioning, which may improve quality of life. The results of this research will be used to determine if Everycell™ is beneficial for overall cellular health and to counteract the effects of aging.
The proposed study is a 6-week, randomized, double-blind, placebo-controlled trial to evaluate the effect of everycell compared to placebo on DNA damage, inflammation, stress, and related factors in 30 healthy adults (18-55 years of age). Participants will be assessed at baseline, 4 weeks (end of intervention), and 6 weeks (2-week washout period), and the study will consist of two treatment arms, including: (a) Everycell and (b) placebo. Additionally, the study will examine subject health-related quality of life (QoL).
Specific Aim. Test the effect of Everycell compared to placebo on DNA damage, inflammation, stress, and related factors in a sample of healthy adults.
Hypothesis. The Everycell group will demonstrate improvements in DNA damage, inflammation, stress, and related factors at 4 and 6-week follow-ups compared to placebo.
Although all measures to protect confidentiality will be put in place, the possibility exists that electronic data could be jeopardized. In the remote case that such event occurs, it will be immediately reported to the IRB.
No substantial psychological, medical, or social risks exist to the participants, other than minor discomfort associated with the venipuncture. The components of everycell should be harmless without significant food allergies. No serious, untoward side effects have been reported to the company by consumers nor observed during previous human studies. If any side effect does occur, the remedy is to discontinue until asymptomatic, and then reintroduce at 1/4 dosage, increasing by the same amount every 2 days, if uneventful, until full dosage is achieved. A toxicology search for each component reveals no unique toxicity characteristic of the materials. As reported by CellHealth Institute, the manufacturer of the product, many customers currently use Everycell, and CellHealth Institute is unaware of significant toxicities.
CellHealth Institute applies the latest scientific methods to ensure the value and safety of their raw materials. CellHealth Institute products are manufactured in state-of-the-art facilities, under strict quality control and environmental protection standards.
Participants will incur no additional appreciable psychological or social risks by participating in this study, although they may undergo psychological and physical discomfort sometimes. The process of interviewing during the assessment may cause discomfort. Discomfort or fatigue may also be experienced in completing the assessment battery.
Alternatives to this study for improving DNA damage, inflammation, and stress include prescription medications, exercise, dietary modification, and other nutritional supplements. The risks of medications can be very significant, including life-threatening, but the risk of taking nutritional supplements is not totally understood, since they are not regulated by the US Food and Drug Administration. Medications and nutritional supplements, as part of a change in lifestyle behaviors, may also prove to be beneficial for DNA damage, inflammation, and stress, but their long-term use has unknown consequences.
The information obtained in this study will help in determining the efficacy of using a nutritional supplement for improving DNA damage, inflammation, and stress outcomes. By participating in the study, subjects may experience improved DNA damage, inflammation, and stress. The risk of participating in this study is reasonable because of the potential enhancements in DNA damage, inflammation, and stress with improved nutritional status.
3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.
This study's enrollment of 30 is below the median of 50 across 2,437 interventional studies indexed under Inflammation.
Browse Inflammation studies →University of Miami is the lead sponsor of 821 studies on the registry; 162 are open to participants now.
Of its 111 completed or terminated interventional studies of FDA-regulated products, 93 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Willing to follow our procedures and requirements for the study, including:
Exclusion Criteria:
Patient will take 1 tablet two times daily of Everycell™ (double-blind) for the 4-week treatment period.
Dietary Supplement: Everycell™
Patient will take 1 tablet two times daily of the placebo (double-blind) for the 4-week treatment period.
Other: Placebo
Also known as: Sugar Pill
Change from Baseline in Nuclear factor kappa-light-chain-enhancer of activated B cells at 4 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 4-week follow-up
Change from Baseline in Fructosamine at 4 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 4-week follow-up
Change from Baseline in Protein Thiol Test at 4 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 4-week follow-up
Change from Baseline in Homocysteine at 4 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 4-week follow-up
Change from Baseline in Telomere Length at 4 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 4-week follow-up
Change from Baseline in Cluster of Differentiation 4 (Regulatory T-cell) at 4 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 4-week follow-up
Change from Baseline in Cluster of Differentiation 8 at 4 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 4-week follow-up
Change from Baseline in Cluster of Differentiation 56 (Natural Killer cell) at 4 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 4-week follow-up
Change from Baseline in 8-hydroxydeoxyguanosine at 4 weeks
Urine sample for 8-OHdG and 8-epi-PGF-2-alpha
Time frame: Baseline, 4-week follow-up
Change from Baseline in 8-epi-PGF-2-alpha at 4 weeks
Urine sample for 8-OHdG and 8-epi-PGF-2-alpha
Time frame: Baseline, 4-week follow-up
Change from Baseline in Forkhead box protein 3 (Regulatory T-cell) at 4 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 4-week follow-up
Change from Baseline in Nuclear factor kappa-light-chain-enhancer of activated B cells at 6 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 6-week follow-up
Change from Baseline in Fructosamine at 6 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 6-week follow-up
Change from Baseline in Protein Thiol Test at 6 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 6-week follow-up
Change from Baseline in Homocysteine at 6 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 6-week follow-up
Change from Baseline in Telomere Length at 6 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 6-week follow-up
Change from Baseline in Cluster of Differentiation 4 (Regulatory T-cell) at 6 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 6-week follow-up
Change from Baseline in Cluster of Differentiation 8 at 6 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 6-week follow-up
Change from Baseline in Cluster of Differentiation 56 (Natural Killer cell) at 6 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 6-week follow-up
Change from Baseline in 8-hydroxydeoxyguanosine at 6 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 6-week follow-up
Change from Baseline in 8-epi-PGF-2-alpha at 6 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 6-week follow-up
Change from Baseline in Forkhead box protein 3 (Regulatory T-cell) at 6 weeks
Blood draw for NF-kB, fructosamine, protein thiol test, homocysteine, telomere length, and CD4/FoxP3 (regulatory T-cells), CD8, and CD56 (NK cell)
Time frame: Baseline, 6-week follow-up
Change from Baseline in Systolic Blood Pressure at 4 weeks
Systolic and diastolic blood pressure measured.
Time frame: Baseline, 4-week follow-up
Change from Baseline in Pulse at 4 weeks
Time frame: Baseline, 4-week follow-up
Change from Baseline in Waist Circumference at 4 weeks
Measure of body composition: waist circumference (cm).
Time frame: Baseline, 4-week follow-up
Change from Baseline in Hip Circumference at 4 weeks
Measure of body composition: hip circumference (cm).
Time frame: Baseline, 4-week follow-up
Change from Baseline in Weight at 4 weeks
Measure of body composition: weight.
Time frame: Baseline, 4-week follow-up
Change from Baseline in Height at 4 weeks
Measure of body composition: height.
Time frame: Baseline, 4-week follow-up
Change from Baseline in Body Mass Index at 4 weeks
Measure of body composition: height and weight to assess BMI.
Time frame: Baseline, 4-week follow-up
Change from Baseline in International Physical Activity Questionnaire at 4 weeks
Time frame: Baseline, 4-week follow-up
Change from Baseline in SF-36v2™ Health Survey at 4 weeks
Time frame: Baseline, 4-week follow-up
Change from Baseline in Systolic Blood Pressure at 6 weeks
Systolic and diastolic blood pressure measured.
Time frame: Baseline, 6-week follow-up
Change from Baseline in Diastolic Blood Pressure at 4 weeks
Systolic and diastolic blood pressure measured.
Time frame: Baseline, 4-week follow-up
Change from Baseline in Diastolic Blood Pressure at 6 weeks
Systolic and diastolic blood pressure measured.
Time frame: Baseline, 6-week follow-up
Change from Baseline in Pulse at 6 weeks
Time frame: Baseline, 6-week follow-up
Change from Baseline in Waist Circumference at 6 weeks
Measure of body composition: waist circumference (cm).
Time frame: Baseline, 6-week follow-up
Change from Baseline in Hip Circumference at 6 weeks
Measure of body composition: hip circumference (cm).
Time frame: Baseline, 6-week follow-up
Change from Baseline in Weight at 6 weeks
Measure of body composition: weight.
Time frame: Baseline, 6-week follow-up
Change from Baseline in Height at 6 weeks
Measure of body composition: height.
Time frame: Baseline, 6-week follow-up
Change from Baseline in Body Mass Index at 6 weeks
Measure of body composition: height and weight to assess BMI.
Time frame: Baseline, 6-week follow-up
Change from Baseline in International Physical Activity Questionnaire at 6 weeks
Time frame: Baseline, 6-week follow-up
Change from Baseline in SF-36v2™ Health Survey at 6 weeks
Time frame: Baseline, 6-week follow-up
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Miami